Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Bullboard Posts
Comment by poneon Jun 12, 2015 6:28pm
35 Views
Post# 23826305

RE:what companies bought what drugs doubling earnings when?

RE:what companies bought what drugs doubling earnings when?

truthseeker2012 wrote:Show me an example of a company at least the size of Cipher or bigger doubling earnings immediately, without having to pay way more than the 40 millions Cipher paid for Innocutis.
[zer0herp are you another fake styless ID made upon June 11 2015 bashing? You said many other drug companies are buying other drugs etc and doubling earnings immediately.
Name at least 3 of the many companies you claim have done this, what drugs etc they bought and what the profits were before and after and when. If you can’t you are most likely, liar, stupidess, styles again. It would only be like the 10th time styless has usee a new ID to bash Cipher.

The only way a company can buy a drug to double earnings immediately would be to pay mega $$$$. I would say at least 10 times or more what the new drug is worth per year, so a drug that could make Ciphers earnings double immediately, 9 million earnings Q1 2015 times 4 is 28 million for 1 year, so I would say it might cost Cipher at least 100 million or more for such a product .

Other then that the buying company would have to have next to no revenues to start with so any new drug would be next to worthless, making it cheap, so yes earnings could be doubled for a company with next to no earnings to start by buying a tiny drug with tiny earnings because even tiny earnings, can be double next to nothing earnings.



What is the earnings of Innocutis? We don't know.

What is the free cash flow of Innocutis? We don't know.

What is the EBITA of Innocutis? We don't know.

Heck, I couldn't even find a figure for revenues at Innocutis.

So what is the value of what we are buying for $40M? We don't know.

I'm not saying it was a bad acquisition. I am saying I don't see a disclosure that lets us value the acquisition. And none of your discussion provides any facts about Innocutis.
Bullboard Posts